Eli Lilly and Company (LLY) – Research Analysts’ Recent Ratings Updates

Eli Lilly and Company (NYSE: LLY) recently received a number of ratings updates from brokerages and research firms:

• 7/18/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/15/2026 – Eli Lilly and Company had its price target raised by Citigroup Inc. from $1,500.00 to $1,600.00. They now have a “buy” rating on the stock.
• 7/14/2026 – Eli Lilly and Company had its price target raised by Sanford C. Bernstein from $1,300.00 to $1,385.00. They now have an “outperform” rating on the stock.
• 7/14/2026 – Eli Lilly and Company had its price target raised by Sanford C. Bernstein from $1,300.00 to $1,385.00. They now have an “outperform” rating on the stock.
• 7/13/2026 – Eli Lilly and Company had its price target raised by UBS Group AG from $1,250.00 to $1,425.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Eli Lilly and Company had its price target raised by Guggenheim from $1,235.00 to $1,273.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Eli Lilly and Company had its price target raised by Bank of America Corporation from $1,251.00 to $1,334.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Eli Lilly and Company was given a new $1,370.00 price target by UBS Group AG.
• 7/8/2026 – Eli Lilly and Company had its price target raised by Truist Financial Corporation from $1,281.00 to $1,370.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,344.00 to $1,347.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Eli Lilly and Company had its price target raised by Royal Bank Of Canada from $1,250.00 to $1,500.00. They now have an “outperform” rating on the stock.
• 7/7/2026 – Eli Lilly and Company had its price target raised by JPMorgan Chase & Co. from $1,300.00 to $1,400.00. They now have an “overweight” rating on the stock.
• 7/6/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,230.00 to $1,350.00. They now have an “overweight” rating on the stock.
• 7/1/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 6/25/2026 – Eli Lilly and Company had its price target raised by Leerink Partners from $1,119.00 to $1,232.00. They now have an “outperform” rating on the stock.
• 6/22/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/22/2026 – Eli Lilly and Company had its price target raised by Berenberg Bank from $1,050.00 to $1,135.00. They now have a “hold” rating on the stock.
• 6/15/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets.
• 6/9/2026 – Eli Lilly and Company had its price target raised by Jefferies Financial Group Inc. from $1,330.00 to $1,350.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Sanford C. Bernstein.
• 6/5/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.